Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT-B: Reducing Vertical Transmission of Hepatitis B in Africa
NCT04704024Phase 3Active, not recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir disoproxil fumarate, lamivudine in hepatitis B (HBV), sponsored by University of Alabama at Birmingham. Started Sep 2021; status: active, not recruiting.
02
Drugs
tenofovir disoproxil fumaratelamivudine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04704024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704024.